Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.

Gastroentérologie clinique et biologique

Salles N, Dussarat P, Foucher J, Villars S, De Lédinghen V

2009 Gastroenterol. Clin. Biol. Volume 33 Issue 2

PubMed 19193508 DOI 10.1016/j.gcb.2008.12.003

FibroTest Reliability Independant Team vs. Elastography Fibrosis Diabetes Hypertension Aged


The objective of this study was to evaluate liver fibrosis using non-invasive methods in elderly patients.


In a prospective two-day study, all consecutive patients of geriatric units were examined using transient elastography (FibroScan) and biochemical markers (Hepascore, Aspartate Transaminase (AST) to platelet ratio index [APRI], Forns score, FibroTest). Three groups of patients were included: elderly patients without liver disease (group A, 85.2+/-7.3 years); healthy younger control subjects without liver fibrosis (group B, 46.4+/-15.2 years); and elderly patients with confirmed liver disease (group C, 82.4+/-2.3 years).


FibroScan) results in the elderly patients correlated well with fibrosis surrogates, but were more difficult to obtain than in the younger subjects. Mean liver stiffness was 6.1 kPa (group A) versus 4.9 kPa (group B) and versus 10.2 kPa (group C) (P<0.0001). FibroTest results were 0.5 in group A versus 0.2 in group B, and versus 0.6 in group C (P<0.0001). In group A, statistical analysis showed that diabetes was associated with advanced liver fibrosis (FibroScan) > or = 9.5 kPa). A body mass index greater than 26kg/m2, age greater than 85 years, comorbidity score and polymedication were not associated with fibrosis.


Although liver stiffness may be more difficult to assess in the elderly, FibroScan may nevertheless serve as a new, non-invasive method for detecting liver fibrosis in this population.

Citation Reference: